EGFR and lung cancer: To the best of our best knowledge, this review is the first meta-analysis for the EGFR mutation rate especially in GGOs, which shows that with the progression in radiological, there is no significant difference in the rate of EGFR mutation (p ≥ 0.05), suggesting that EGFR mutation, as a driver mutation for lung cancer, count for tumorigenesis in a relatively early stage, and maintain consistency in the progression of tumors.